The third Sino-German Cross-Border Pharmaceutical Health Industry Cooperation and Exchange Conference was held Nov. 3 at Beijing's Daxing Biomedicine Industrial Base, focusing on promoting Chinese medicines overseas.

A Daxing district official said the conference highlights the area's potential as a launch pad for pharmaceutical companies to accelerate international expansion, driving shared benefits within what's dubbed "China Pharmaceutical Valley."

More than 20 companies from the area have already entered global markets, with numerous products now sold overseas. For example, Biocytogen generates nearly 70% of its sales from international business and, in the first half of this year, signed cooperation agreements with overseas firms worth hundreds of billions of yuan.

Meanwhile, Minhai Biotechnology has distributed vaccines to Southeast Asia, the Middle East and South America and is seeking to attract global research teams to establish an international vaccine innovation center.

This year, the valley launched a comprehensive export service platform that integrates resources from government departments, industry organizations, and overseas organizations. The platform provides policy support, professional services and corporate guidance to help firms expand internationally. This collaborative structure allows experienced companies to share their market channels, making it easier for Chinese products to reach global customers.

"Going global is a difficult yet correct path, requiring robust technologies and a global perspective," said Ma Xianyin, director of the base's management committee. Greater openness, Ma said, leads to increased vitality and growth for China Pharmaceutical Valley.